Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study

Assmann, 1996, Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men, Am J Cardiol, 77, 1179, 10.1016/S0002-9149(96)00159-2 Hokanson, 1996, Plasma triglyceride levels is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies, J Cardiovasc Risk, 3, 213, 10.1097/00043798-199604000-00014 Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299 2002, National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Kris-Etherton, 2002, Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease, Circulation, 106, 2747, 10.1161/01.CIR.0000038493.65177.94 Teramoto, 2007, Goals of dyslipidemia management- executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese, J Atheroscler Thromb, 14, 209, 10.5551/jat.E554 Yokoyama, 2003, Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS), Am Heart J, 146, 613, 10.1016/S0002-8703(03)00367-3 Burr, 1989, Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART), Lancet, 334, 757, 10.1016/S0140-6736(89)90828-3 1999, Dietary supplementation with n-3polyunsaturated fatty acids with vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5 Marchioli, 2002, Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction, Circulation, 105, 1897, 10.1161/01.CIR.0000014682.14181.F2 Wang, 2006, n-3 fatty acids from fish or fish-oil supplements, but not α-linoleic acid, benefit cardiovascular disease outcomes in primary- and secondary—prevention studies: a systematic review, Am J Clin Nutr, 84, 5, 10.1093/ajcn/84.1.5 Iso, 2006, Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I, Circulation, 113, 195, 10.1161/CIRCULATIONAHA.105.581355 Hooper, 2004, Omega 3 fatty acids for prevention and treatment of cardiovascular disease (review), Cochrane Database Syst Rev, 4, CD003177 Maki, 2009, Omega-3 fatty acids for the treatment of elevated triglycerides, Clin Lipidol, 4, 425, 10.2217/clp.09.34 McKenney, 2007, Prescription omega-3 fatty acids for the treatment of hyperetriglyceridemia, Am J Health Syst Pharm, 64, 595, 10.2146/ajhp060164 Harris, 2006, Why do omega-3 fatty acids lower serum triglycerides?, Curr Opin Lipidol, 17, 387, 10.1097/01.mol.0000236363.63840.16 Harris, 2008, Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives, Atherosclerosis, 197, 12, 10.1016/j.atherosclerosis.2007.11.008 Bays, 2008, Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications, Expert Rev Cardiovasc Ther, 6, 391, 10.1586/14779072.6.3.391 Harris, 1997, Safety and efficacy of Omacor in severe hypertiglyceridemia, J Cardiovasc Risk, 4, 385, 10.1097/00043798-199710000-00011 Borthwick, 1998, The effects of omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia, Clin Drug Invest, 15, 397, 10.2165/00044011-199815050-00004 Bays, 2010, Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients, Curr Med Res Opin, 26, 907, 10.1185/03007991003645318 Davidson, 2009, Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia, J Clin Lipidol, 3, 332, 10.1016/j.jacl.2009.08.001 Robinson, 2006, Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids, Am J Cardiol, 4, 39, 10.1016/j.amjcard.2005.12.026 Ballantyne, 2012, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study), Am J Cardiol, 110, 984, 10.1016/j.amjcard.2012.05.031 Bays, 2011, Eicosapentaenoic acid ethyl ester (AMR 101) therapy in patients with very high triglyceride levels (from the Muticenter, plAcebo-controlled, Randomized, double-bliNd, 12-week study with an open-label Extension [MARINE] Trial), Am J Cardiol, 108, 682, 10.1016/j.amjcard.2011.04.015